Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.66 |
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.66 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.66 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17460287 | 0.90 | CSF1R (0.62) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL2850002 | 0.86 | MEN1 (0.67) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL4226386 | 0.85 | PLAU (0.55) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL3462271 | 0.85 | MEN1 (0.72) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL4004339 | 0.85 | KCNK3 (0.76) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL5425792 | 0.85 | MEN1 (0.65) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL28280295 | 0.85 | MEN1 (0.65) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL23932088 | 0.84 | KMT2A (0.66) | MEN1KMT2AKCNK3KCNK9 | |
| SCHEMBL408480 | 0.83 | PARP1 (0.63) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL895690 | 0.83 | MEN1 (0.63) | PARP1PARP10PARP15PARP14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | claimed |
| CN-109689664-A | The quinoline and azepine quinoline compound that tricyclic heteroaryl as PAR4 inhibitor replaces | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | claimed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-109689664-A | The quinoline and azepine quinoline compound that tricyclic heteroaryl as PAR4 inhibitor replaces | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | disclosed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | PARP1 2851/4885PARP10 1193/4885PARP15 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.